Advanced search

Ms. Mardi C. Dier is a Chief Financial Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc., an Independent Director at Oric Pharmaceuticals, Inc. and an Independent Director at Adamas Pharmaceuticals, Inc. She is on the Board of Directors at Prelude Therapeutics, Inc., Oric Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. Ms. Dier was previously employed as a CFO, Chief Business Officer & Executive VP by Portola Pharmaceuticals, Inc., a Vice President-Investor Relations by Chiron Corp., a Director-Investment Banking by Prudential Equity Group LLC, a Senior Accountant by KPMG LLP, a Senior Accountant by KPMG Peat Marwick LLP, and a Director-Investment Banking by Prudential Securities. She also served on the board at Jewish Vocational Service, Inc. and Futures Strategic Trust. She received her undergraduate degree from Stanford University and an MBA from UCLA Anderson School of Management.

Gregory Dier worked as an Associate Research Analyst at Hartford Investment Management Co..
Mr. Dier attended Middlebury College, where he received an undergraduate degree in 2013.

James G.
Dier, who previously worked at Thrivent Investment Management, Inc., held the position of Director.

Louise Dier served as an Independent Non-Executive Director at TClarke Plc from 2019 to 2022.
Prior to that, she worked as a Managing Director at David Chipperfield Architects Ltd., General Manager-United Kingdom at DO & CO Catering-Consult & Beteiligungs GmbH, and Head-Human Resources at IMG Europe Ltd.
She graduated from the University of Cambridge.

Martina Dier has a current job as the Director of Global Communications at TeamViewer SE.

Mardi Loho worked at PT ICTSI Jasa Prima Tbk from 1994 to 2012.
During his time there, he held the position of Independent Commissioner from 2011 to 2012.